Literature DB >> 6174449

Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain.

S B Formal, L S Baron, D J Kopecko, O Washington, C Powell, C A Life.   

Abstract

Shigella sonnei, an intestinal pathogen, produces a characteristic form I cell surface antigen now known to be plasmid encoded. We considered that the GalE Salmonella typhi Ty21a oral vaccine strain, highly effective against typhoid, might be modified so as to be protective also against shigellosis due to S. sonnei. The plasmid responsible for form I antigen synthesis was therefore conjugally transferred to the galE S. typhi strain. Serological studies revealed that the derivative strain produces the form I antigen in addition to the normal S. typhi somatic antigens. Testing in mice demonstrated that the derivative form I galE S. typhi strain is protective against both S. sonnei and S. typhi challenges. These data suggest that the galE S. Ty21a oral vaccine strain, which presumably stimulates the local immune system in the intestine, may also serve as a useful carrier for other antigenic determinants to protect against different intestinal infections.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6174449      PMCID: PMC350934          DOI: 10.1128/iai.34.3.746-750.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  CONTROLLED FIELD TRIAL IN BRITISH GUIANA SCHOOL CHILDREN OF HEAT-KILLED-PHENOLIZED AND ACETONE-KILLED LYOPHILIZED TYPHOID VACCINES.

Authors:  M T ASHCROFT; J M RITCHIE; C C NICHOLSON
Journal:  Am J Hyg       Date:  1964-03

2.  Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment.

Authors:  A R HIGGINS; T M FLOYD; M A KADER
Journal:  Am J Trop Med Hyg       Date:  1955-03       Impact factor: 2.345

3.  Mutants of Escherichia coli requiring methionine or vitamin B12.

Authors:  B D DAVIS; E S MINGIOLI
Journal:  J Bacteriol       Date:  1950-07       Impact factor: 3.490

4.  Failure of parenteral vaccines to protect monkeys against experimental shigellosis.

Authors:  S B Formal; R M Maenza; S Austin; E H LaBrec
Journal:  Proc Soc Exp Biol Med       Date:  1967-06

5.  Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine.

Authors:  R Germanier; E Füer
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

6.  [Correlation between the loss of plasmid DNA and the transition from virulent phase I to avirulent phase II in Shigella sonnei].

Authors:  P Sansonetti; M David; M Toucas
Journal:  C R Seances Acad Sci D       Date:  1980-03-31

7.  Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine.

Authors:  R H Gilman; R B Hornick; W E Woodard; H L DuPont; M J Snyder; M M Levine; J P Libonati
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

8.  Simple agarose gel electrophoretic method for the identification and characterization of plasmid deoxyribonucleic acid.

Authors:  J A Meyers; D Sanchez; L P Elwell; S Falkow
Journal:  J Bacteriol       Date:  1976-09       Impact factor: 3.490

9.  Genetic and physical evidence for plasmid control of Shigella sonnei form I cell surface antigen.

Authors:  D J Kopecko; O Washington; S B Formal
Journal:  Infect Immun       Date:  1980-07       Impact factor: 3.441

10.  Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial.

Authors:  D M Mel; A L Terzin; L Vuksić
Journal:  Bull World Health Organ       Date:  1965       Impact factor: 9.408

View more
  46 in total

Review 1.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 2.  Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens.

Authors:  L Cárdenas; J D Clements
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

Review 3.  Outer membrane protein PhoE as a carrier for the exposure of foreign antigenic determinants at the bacterial cell surface.

Authors:  M Agterberg; J Tommassen
Journal:  Antonie Van Leeuwenhoek       Date:  1991-05       Impact factor: 2.271

4.  Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine.

Authors:  D M Hone; C O Tacket; A M Harris; B Kay; G Losonsky; M M Levine
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

Review 5.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

6.  Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers.

Authors:  J X Bao; J D Clements
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

Review 7.  New aspects of vaccine development.

Authors:  F Y Liew
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

8.  Intestinal immunoglobulin A responses in rabbits to a Salmonella typhi strain harboring a Shigella sonnei plasmid.

Authors:  D F Keren; H H Collins; L S Baron; D J Kopecko; S B Formal
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

9.  Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen.

Authors:  S B Formal; T L Hale; C Kapfer; J P Cogan; P J Snoy; R Chung; M E Wingfield; B L Elisberg; L S Baron
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

Review 10.  Oral vaccination against enteric bacterial infections: an overview.

Authors:  R Germanier
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.